Patients
mature T/NK-cell neoplasms
MAY, DISEASE, BLOOD DISORDERS
Patients with mature T/NK-cell neoplasms under follow up at the Blood Disorders Center at Aiiku Hospital during the period from May 26, 2021, to August 5, 2022, were included in this study. All of the patients were vaccinated with at least two doses of an mRNA-based COVID-19 vaccine, either BNT162b2 or mRNA-1273. BNT162b2 and mRNA-1273 were administered 21 and 28 days apart, respectively. All disease statuses of patients were determined at the time of the second vaccination. We recruited healthcare workers aged 50 years or older who had received at least two doses of BNT162b2 vaccine as HC. They were unlikely to be transmitted from inpatients since our hospital had not accepted COVID-19 patients. Individuals with a known history of COVID-19 were excluded from both cohorts of patients and HC. This study was a part of a prospective observation study (UMIN 000,045,267, 000,048,764) and it was conducted in compliance with ethical principles based on the Helsinki Declaration and was approved by the institutional review board of Aiiku Hospital. All patients provided written informed consent.